Zafgen to Present at 34th Annual Canaccord Genuity Growth Conference

        Print
| Source: Zafgen, Inc.

BOSTON, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced that Thomas Hughes, Ph.D., Chief Executive Officer, is scheduled to present a company overview at the 34th Annual Canaccord Genuity Growth Conference. The conference is being held August 13th – 14th, 2014 at the InterContinental Hotel in Boston, Massachusetts. Zafgen is scheduled to present on Thursday, August 14, 2014 at 11:00 a.m. ET. A live webcast of the presentation will be available on Zafgen's website, www.zafgen.com.

About Zafgen, Inc.

Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity. Beloranib, Zafgen's lead product candidate, is a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in Prader-Willi syndrome, hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen was founded in 2005 to explore novel approaches to obesity therapeutics, including agents known to inhibit MetAP2 that had been found to drive unprecedented weight loss and metabolic improvements in mice. The company is located in Boston, MA.

Investor Relations Contact:
Brian Ritchie
(212) 850-5683